OnCo
trialsTrialCompleted

Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

A phase 2 trial of Panobinostat in Leukaemia, run by Novartis Pharmaceuticals, completed.